IL-29, human recombinant protein
Interleukin-29, IL-29, IFN-Lambda 1, Interferon-Lambda 1, Cytokine ZCYTO21, IL29, IFNL1, ZCYTO21.
|Calculated MW||20 kDa|
|Other Names||Interleukin-29, IL-29, IFN-Lambda 1, Interferon-Lambda 1, Cytokine ZCYTO21, IL29, IFNL1, ZCYTO21.|
|Application Notes||Reconstitute in sterile dH₂O not less than 100 µg/ml. This solution can then be diluted into other aqueous buffers|
|Storage||-20°C; Sterile filtered and lyophilized with no additives|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor β (IL10RB) and interleukin 28 receptor α. IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-Lambda 1 antiviral and antiproliferative activity requires Interferon-Lambda 2 receptor tyrosine residues. Recombinant human IL-29 produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 181 amino acids and having a molecular mass of 20 kDa.
If you have any additional inquiries please email technical services at email@example.com.